365bet娱乐

CYT387 is an inhibitor of Janus kinases JAK1 and JAK2, acting as an ATP competitor with IC50 values of 11 and 18 nM, respectively. The inhibitor is significantly less active towards other kinases, including JAK3 (IC50 = 0.16 μM).

As of 2011, CYT387 is being developed as a drug for myelofibrosis and currently undergoes Phase I/II clinical trials. Additional potential treatment indications for CYT387 include other myeloproliferative neoplasms, cancer (solid and liquid tumors) and inflammatory conditions.

The drug was originally discovered by Australian drug discovery company Cytopia, then developed by YM BioSciences Inc. (since acquired by Gilead Sciences as of 2013)

Product Details:

Name: Momelotinib

Synonyms:

N-(Cyanomethyl)-4-(2-((4-morpholinophenyl)-amino)pyrimidin-4-yl)benzamide;

CYT387;

N-(Cyanomethyl)-4-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)benzamide;

CAS: 1056634-68-4

EINECS: N/A

MF: C23H22N6O2

MW: 414.46000

Purity: 95%min

Density: 1.292

Storage condition: Store in a cool, dry, well-ventilated area away from incompatible substances.

Acidity factor (pKa): 10.94±0.46(Predicted)

Appearance: Orange powder.

Package: 5g, 25g, 100g, 500g, 1kg, 25kg

Hot Tags: momelotinib cas: 1056634-68-4, China, manufacturers, in stock, free sample, high quality, low price, CAS 1571 30 8, CAS 100501 62 0, CAS 1450 94 8, 3 5 cyclic AMP, CAS 90607 21 9, CAS No 1003845 06 4